# Personalizing DNA Cancer Vaccines

## TL;DR

This paper reviews how DNA vaccines are being personalized to target cancer-specific mutations and boost immune responses.

## Contribution

The paper provides a comprehensive overview of strategies and technologies for developing personalized DNA cancer vaccines.

## Key findings

- DNA vaccines are being tailored to target tumor-specific neoantigens for personalized cancer immunotherapy.
- Advances in molecular biology and computational tools have improved neoantigen identification and vaccine design.
- Current challenges include optimizing delivery platforms and ensuring clinical efficacy of personalized DNA vaccines.

## Abstract

Recent progress in tumor immunotherapy highlights the important role of the immune system in combating various cancers. Traditionally designed to protect against infectious diseases, vaccines are now being adapted to stimulate immune responses against tumor-specific neoantigens. Both preclinical studies and clinical trials have explored innovative approaches for identifying neoantigens and optimizing vaccine design, advancing the field of personalized oncology. Among these, DNA-based vaccines have become a particularly attractive approach for cancer immunotherapy. This evolution has been driven by improvements in molecular biology techniques, including more precise methods for detecting tumor-specific mutations, computational tools for predicting immunogenic antigens, and novel platforms for delivering nucleic acid vaccines. Personalized DNA vaccines are typically developed through a complex, multi-step process that involves sequencing a patient’s tumor, computational analysis to identify potential targets, and custom vaccine production. In this review, we examine the use of both shared tumor antigens and individualized neoantigens in cancer vaccine development. We outline strategies for neoantigen identification that provide insights into tumor-specific alterations. Furthermore, we highlight recent advances in DNA vaccine technologies, address the current limitations facing cancer vaccines, propose strategies to overcome these challenges, and consider key clinical and technical factors for successful implementation.